Solid Biosciences Inc expected to post a loss of 48 cents a share - Earnings Preview

Solid Biosciences

07/08/2026 22:05

Solid Biosciences Inc SLDB.OQ SLDB.O is expected to  show no change in quarterly revenue when it reports  results on November 2 (estimated) for the period ending September 30 2026

​LSEG's mean analyst estimate for Solid Biosciences Inc is for a loss of 48 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts had fallen by about 17.4% in the last three months. ​
Wall Street's median 12-month price target for Solid Biosciences Inc is $16.00, about 83.7% above its last closing price of $8.71
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Jun. 30 2026
-0.46
-0.47
-0.38
Beat
18.8
Mar. 31 2026
-0.44
-0.43
-0.52
Missed
-19.9
Dec. 31 2025
-0.53
-0.52
-0.53
Missed
-2.1​
Sep. 30 2025
-0.44
-0.44
-0.48
Missed
-9.4
​​Jun. 30 2025
-0.48
-0.50
-0.42
Beat
16.7
Mar. 31 2025
-0.53
-0.56
-0.59
Missed
-6.1​
Dec. 31 2024
-0.81
-0.81
-1.00
Missed
-24
Sep. 30 2024
-0.66
-0.67
-0.79
Missed
-18.3
This summary was machine generated August 7 at 21:05 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)